

BJA education.
v. 16, no. 9 (Sept. 2016)
General Collection
W1 BJ102
2016-10-06 07:01:41


BJA

Education

Editor-in-Chief: Jeremy A. Langton



Volume 16 | Number 9 | September 2016 | ISSN 2058-5349 (PRINT) 2058-5357 (ONLINE)
Previously known as *Continuing Education in Anaesthesia, Critical Care and Pain*



In this month's issue:

Diastolic dysfunction in anaesthesia and critical care • Intravenous lidocaine for acute pain: an evidence-based clinical update • Non-invasive ventilation in the perioperative period • Phosphate homeostasis in critical care
• Measurement in pain medicine • Heritable connective tissue diseases, vasculitides, and the anaesthetist

OXFORD
UNIVERSITY PRESS

www.bjaed.oxfordjournals.org

OXFORD  OPEN

SUBSCRIPTIONS

A subscription to *BJA Education* (formerly *Continuing Education in Anaesthesia, Critical Care & Pain* (CEACCP)) comprises twelve issues. Prices include postage by surface mail, or for subscribers in the US and Canada by airfreight, or in India, Japan, Australia and New Zealand by Air Speeded Post. Airmail rates are available on request.

BJA Education is received by all Fellows of the Royal College of Anaesthetists, the Intensive Care Society, members of the Pain Society and Fellows of the College of Anaesthetists of Ireland. All Fellows and members, world-wide, should notify changes of address directly to their respective College or Society.

Annual Subscription Rate (Volume 16, 12 issues, 2016)

Institutional

Print edition and site-wide online access: £218/\$415/€328

Print edition only: £201/\$382/€301

Site-wide online access only: £175/\$332/€262

Personal

Print edition: £89/\$173/€134

Please note: US \$ rate applies to US and rest of world, except UK (£) and Europe (€).

There may be other subscription rates available; for a complete listing, please visit the journal web site: <http://bjaed.oxfordjournals.org>

Full prepayment, in the correct currency, is required for all orders. Orders are regarded as firm and payments are not refundable. Subscriptions are accepted and entered on a complete-volume basis. Claims cannot be considered more than FOUR months after publication or date of order, whichever is later. All subscriptions in Canada are subject to GST. Subscriptions in the EU may be subject to European VAT. If registered, please supply details to avoid unnecessary charges. For subscriptions that include online versions, a proportion of the subscription price may be subject to UK VAT. Personal rate subscriptions are only available if payment is made by personal cheque or credit card and delivery is to a private address.

The current year and two previous years' issues are available from Oxford Journals. Previous volumes can be obtained from the Periodicals Service Company at <http://www.periodicals.com/oxford.html> or Periodicals Service Company, 11 Main Street, Germantown, NY 12526, USA. Email: psc@periodicals.com; <http://www.periodicals.com/oxford.html>; Tel: 1 (518) 537 4700; Fax: 1 (518) 537 5899.

For further information, please contact: Journals Customer Service Department, Oxford University Press, Great Clarendon Street, Oxford OX2 6DP, UK. Email: jnlcust.serv@oup.com; Tel (and answerphone outside normal working hours): 44 (0)1865 353907; Fax: 44 (0)1865 353485. **In the US, please contact:** Journals Customer Service Department, Oxford University Press, 2001 Evans Road, Cary, NC 27513, USA. Email: jnlorders@oup.com; Tel (and answerphone outside normal working hours): 800 852 7323 (toll-free in USA/Canada); Fax: 919 677 1714. **In Japan, please contact:** Journals Customer Services, Oxford University Press, 4-5-10-8F, Shiba, Minato-ku, Tokyo 108-8386, Japan. Email: custserv.jp@oup.com; Tel: (03) 5444 5858; Fax: (03) 3454 2929.

Methods of payment. (i) Cheque (payable to Oxford University Press, to Oxford University Press, Cashiers Office, Great Clarendon Street, Oxford OX2 6DP, UK) in GBE Sterling (drawn on a UK bank), US\$ Dollars (drawn on a US bank), or EU€ Euros. (ii) Bank transfer to Barclays Bank Plc, Oxford Group Office, Oxford (bank sort code 20-65-18) (UK), overseas only Swift code BARC GB 22 (GBE Sterling to account no. 70299332, IBAN GB89BARC20651870299332; US\$ Dollars to account no. 66014600, IBAN GB27BARC20651866014600; EU€ Euros to account no. 78923655, IBAN GB16BARC20651878923655). (iii) Credit card (Mastercard, Visa, Switch or American Express).

BJA Education (formerly *Continuing Education in Anaesthesia, Critical Care & Pain*) is published monthly by Oxford University Press, Oxford, UK. Annual subscription price is £218/\$415/€328 (for Institutional Subscribers). Airfreight and mailing in the USA by agent named Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA. Periodicals postage paid at Jamaica NY 11431.

US Postmaster: Send address changes to *BJA Education*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

Subscription records are maintained at Oxford University Press, Great Clarendon Street, Oxford OX2 6DP, UK.

REPRINTS AND CORPORATE SALES

For requests from industry and companies regarding supplements, bulk article reprints, sponsored subscriptions, translation opportunities for previously published material, and corporate online opportunities, please email special.sales@oup.com, fax 44 (0)1865 353774 or visit http://www.oxfordjournals.org/corporate_services/

OXFORD JOURNALS ENVIRONMENTAL AND ETHICAL POLICIES

Oxford Journals is committed to working with the global community to bring the highest quality research to the widest possible audience. Oxford Journals will protect the environment by implementing environmentally friendly policies and practices wherever possible. Please see <http://www.oxfordjournals.org/ethicalpolicies.html> for further information on Oxford Journals' environmental and ethical policies

DOIs

For information about DOI's and how to resolve them, please visit <http://dx.doi.org>

PERMISSIONS

For information on how to request permissions to reproduce articles/information from this journal, please visit http://www.oxfordjournals.org/access_purchase/rights_permissions.html

ADVERTISING

Advertising, inserts and artwork enquiries should be addressed to Advertising and Special Sales, Oxford Journals, Oxford University Press, Great Clarendon Street, Oxford, OX2 6DP, UK. Tel: +44 (0)1865 354767; Fax: +44 (0)1865 353774; E-mail: jnladsales@oup.com

DRUG DISCLAIMER

The mention of trade names, commercial products or organizations and the inclusion of advertisements in the journal does not imply endorsement by the Board of Management and Trustees of the British Journal of Anaesthesia, the Royal College of Anaesthetists, the editors, the editorial board, Oxford University Press or the organization to which the authors are affiliated. The editors and publishers have taken all reasonable precautions to verify drug names and doses, the results of experimental work and clinical findings published in the journal. The ultimate responsibility for the use and dosage of drugs mentioned in the journal and in interpretation of published material lies with the medical practitioner, and the editors and publishers cannot accept liability for damages arising from any errors or omissions in the journal. Please inform the editors of any errors.

DISCLAIMER

Statements of fact and opinion in the articles in *BJA Education* are those of the respective authors and contributors and not of the Board of Management and Trustees of the British Journal of Anaesthesia, the Royal College of Anaesthetists, or Oxford University Press. Neither Oxford University Press nor the Board of Management and Trustees of the British Journal of Anaesthesia, the Royal College of Anaesthetists, make any representation, express or implied, in respect of the accuracy of the material in this journal and cannot accept any legal responsibility or liability for any errors or omissions that may be made. The reader should make his/her own evaluation as to the appropriateness or otherwise of any experimental technique described.

PLAGIARISM

The Editors of *BJA Education* use plagiarism detection software on all submitted material.

© The British Journal of Anaesthesia 2016

All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission of the Publishers, or a licence permitting restricted copying issued in the UK by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1P 9HE, or in the USA by the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923.

Typeset by Nova Techset Private Limited, Bengaluru & Chennai, India
Printed by Bell and Bain Ltd, Glasgow, UK



Contents



The Royal College of Anaesthetists



Faculty of Pain Medicine



College of Anaesthetists of Ireland



The Hong Kong College of Anaesthesiologists

The Faculty of Intensive Care Medicine

Diastolic dysfunction in anaesthesia and critical care	287
GEP Godfrey, MJE Peck	
Intravenous lidocaine for acute pain: an evidence-based clinical update	292
N Eipe, S Gupta, J Penning	
Non-invasive ventilation in the perioperative period	299
K Bauchmuller, AJ Glossop	
Phosphate homeostasis in critical care	305
RL Wadsworth, S Siddiqui	
Measurement in pain medicine	310
T Bendinger, N Plunkett	
Heritable connective tissue diseases, vasculitides, and the anaesthetist	316
S Chetcuti, RB Jones, J Varley	

Cover caption: Abraham Lincoln. Portrait of Abraham Lincoln (1809-1865), 16th president of the USA and a sufferer of Marfan's syndrome. Marfan's syndrome is a hereditary disorder characterized by excessive tallness, long slender fingers and heart defects. Lincoln's leaness, thin head and sunken breast were because of his condition. Lincoln is best known as the president who led his country through the Civil War (1861-1865) and who liberated the southern slaves. He was assassinated by the actor John Wilkes Booth whilst at the theatre.

Credit: LIBRARY OF CONGRESS/SCIENCE PHOTO LIBRARY.



Scan to view this journal on your mobile device

Editorial Board

Jeremy A Langton – Editor-in-Chief, Plymouth

Editors

Dylan Bould, Ottawa
Daniele Bryden, Sheffield
David Coventry, Dundee
Andrew Farmery, Oxford
William Fawcett, Guildford
Nick Fletcher, London
Alexander P L Goodwin, Bath
Ashish Gulve, Middlesbrough
W Hiu Lam, Plymouth

Andy Lumb, Leeds
Peter MacNaughton, Plymouth
Connail McCrory, Dublin
Vivek Mehta, London
Gary H Mills, Sheffield
Alexander Ng, Birmingham
Felicity Plaat, London
Jonathan Smith, London
Cameron J Weir, Dundee

Trainee editors (and podcasts)

Benjamin Marriage, Cambridge
Cliff Shelton, Manchester

*Articles marked with  have a related podcast available online.

All articles have associated MCQs to support CME/CPD activity. These can be accessed at <https://access.oxfordjournals.org> by subscribers to *BJA Education*.

Please visit the Journal's World Wide Web site at <http://bjaed.oxfordjournals.org>

Address for correspondence:

Dr J A Langton MD FRCA, Editor-in-Chief, email bjaeducation@rcoa.ac.uk

BJA Education | Volume 16 Number 9 2016

Phosphate homeostasis in critical care

RL Wadsworth MB ChB FRCA¹ and S Siddiqui MB ChB FRCA^{2,*}

¹Advanced Trainee in Intensive Care Medicine, Sheffield Teaching Hospitals NHS Trust, Herries Road, Sheffield S5 7AU, UK and ²Consultant in Anaesthesia and Intensive Care Medicine, Barnsley Hospital NHS Foundation Trust, Gawber Road, Barnsley S75 2EP, UK

*To whom correspondence should be addressed. Tel: +44 1226 432022; E-mail: sughrat@gmail.com

Key points

- Serum phosphate is under tight physiological control.
- Hypophosphataemia is common in hospitalized patients, particularly in the critically ill.
- Hypophosphataemia causes multisystem effects if left untreated.
- Phosphate disturbances are often multifactorial.
- Treatment of hyperphosphataemia secondary to rhabdomyolysis or tumour lysis syndrome should be instituted promptly.

Phosphorus plays a critical role in many biological processes, including energy metabolism, cellular signalling, nucleic acid metabolism, membrane integrity, and bone mineralization.¹ Phosphate is an inorganic molecule containing four oxygen atoms and a central phosphorus atom. In its ionic form, phosphate (PO_4^{3-}) is negatively charged, leading it to be an ideal buffer and easily combining with positively charged calcium ions to contribute to hydroxyapatite, the main mineral component of bone, where up to 85% of the body's phosphate stores exist.

Physiology

Phosphorus in the diet is present in inorganic and organic forms. Organic phosphorus is absorbed less freely than inorganic phosphate. Phosphate absorption is highly efficient, with 60–70% of an intestinal load absorbed from a typical diet,² occurring mostly in the duodenum and jejunum.

Intestinal absorption occurs both by non-regulated passive transport through the paracellular pathway and regulated active mechanisms³ via type IIb sodium phosphate co-transporters on the mucosal surfaces. Intracellular transport and export via the basolateral membrane is likely related to movement down the concentration gradient to the relatively low serum concentration.

Three families of sodium/phosphorus (Na/Pi) co-transporters exist. Type I is present in the kidneys and liver, type II in the kidney, small intestine and lung, and type III in most areas of the body.

Plasma phosphorus consists of phospholipids, ester phosphates, and inorganic phosphates. Inorganic phosphates are completely ionized, circulating primarily as hydrogen phosphate $\text{H}(\text{PO}_4)^{2-}$ or dihydrogen phosphate $\text{H}_2(\text{PO}_4)^{-}$ in a ratio of 4:1 at a plasma pH of 7.40.⁴

Phosphate and calcium share an intimate relationship, not least due to the high mineral content of the bone comprising combinations of these molecules. Hydroxyapatite has the formula $\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$ and provides bone with its compressional strength. Also hydroxyapatite, calcium, and phosphate co-exist in the bone as exchangeable forms of salts, such as CaHPO_4 and other amorphous calcium salts. These are in equilibrium with the calcium ions in the extracellular fluids, importantly providing a rapid buffering mechanism to prevent the calcium ion concentration from altering. The calcium ion concentration is therefore under tight control of within a few per cent of the normal level of $1.2 \text{ mmol litre}^{-1}$.

The plasma concentrations of phosphate and calcium are small in proportion to the total body content, but it is these parameters that are under hormonal control (Fig. 1).

Vitamin D3 (cholecalciferol) is a fat-soluble steroid synthesized in the skin, as a result of irradiation of 7-dehydroxycholesterol by ultraviolet rays. It is also present in a similar form in the diet. It is activated by a hepatic enzyme, 25-hydroxylase, placing a hydroxyl group in the 25 position of the vitamin D molecule, resulting in the formation of 25-hydroxycholecalciferol (calcidiol). Further,




Fig 1 Hormonal control of phosphate. PTH, parathyroid hormone.

conversion to its most active form, 1,25-dihydroxycholecalciferol (calcitriol), occurs in the proximal tubules of the kidneys with negative feedback at each stage by 25-hydroxycholecalciferol, and parathyroid hormone, respectively. Hypophosphataemia also encourages the conversion of 25-hydroxycholecalciferol to 1,25-dihydroxycholecalciferol.

1,25-Dihydroxycholecalciferol raises calcium and phosphate levels by increasing gut absorption. Here, the type IIb sodium phosphate co-transporter appears to be regulated at the membrane level by 1,25-dihydroxycholecalciferol, but not at a transcriptional level. 1,25-Dihydroxycholecalciferol also increases activity of the osteoblasts, laying down calcium into the bone matrix and increases calcium and phosphate reabsorption by the epithelial cells of the renal tubules.

Parathyroid hormone is released in response to changes in calcium concentration but also acts on phosphate. As parathyroid levels increase, the bone releases calcium and phosphate-containing minerals into the circulation. Parathyroid hormone also has a direct effect on the kidney to increase tubular reabsorption of calcium, but also to decrease the phosphate reabsorption by acting on the proximal tubules. The net effect is that phosphate levels decrease in response to parathyroid hormone. Parathyroid hormone also promotes formation in the kidneys of 1,25-dihydroxycholecalciferol, therefore enhancing the absorption of calcium and phosphate from the gastrointestinal (GI) tract.

Phosphate is completely reabsorbed by the kidney when the plasma concentration is below 1 mmol litre⁻¹ with none lost to the urine. Above this critical concentration, phosphate loss is proportional to the concentration present.

Hypophosphataemia

Up to 5% of hospitalized patients may have low serum phosphate concentrations <0.8 mmol litre⁻¹, but this is more common in critically ill patients.⁵ One study of 2730 critically ill patients in

Australia reported an incidence as high as 26%.⁶ Profound hypophosphataemia (<0.32 mmol litre⁻¹), which can lead to physiological disturbances, is much less common however.

There are four mechanisms by which hypophosphataemia can occur:

- (i) redistribution,
- (ii) decreased absorption,
- (iii) increased renal loss,
- (iv) renal replacement therapies.

Critical care patients and those undergoing surgery commonly have multiple risk factors that may lower phosphate levels. This is particularly true for major surgery, such as cardiac surgery and abdominal aortic surgery.⁷ After major hepatic surgery, hypophosphataemia is extremely frequent.⁷ Internal redistribution is the most common cause in these physiologically stressed patients. Glycolysis causes an increase in the phosphorylated compounds in the liver and skeletal muscle, the source of which is the inorganic phosphate in extracellular fluid. The use of insulin, or stimulation of increased endogenous insulin secretion, will cause a decrease in serum phosphate levels by moving phosphate intracellularly along with glucose. Epinephrine, glucagon, and other hormones also produce this effect by a similar mechanism (Table 1). This can become more problematic in patients with underlying phosphate depletion—such as those who are fasted for prolonged periods, malnourished due to chronic alcohol intake, or anorexia nervosa. During the anabolic period, after re-feeding, there is an influx of phosphate into the cells which can lead to a severe hypophosphataemia. This is the primary manifestation of the 're-feeding syndrome'.

Patients with hyperglycaemia, and subsequent osmotic diuresis (and therefore loss of phosphate in the urine) who are treated with insulin, are at risk of hypophosphataemia, and this should be monitored closely and corrected as necessary.

Another redistributive cause of hypophosphataemia is respiratory alkalosis.⁸ Extracellular decreases in carbon dioxide will result

Table 1 Causes of hypophosphataemia

Internal redistribution	
Hormonal triggers	Insulin, glucagon, epinephrine, dopamine
Drugs	Carbohydrate infusions, β -2 agonists, steroids, xanthine derivatives
Respiratory alkalosis	Mechanical ventilation, sepsis, alcohol withdrawal, hepatic coma, anxiety, salicylate overdose
Glucose shifts	Treatment of DKA, re-feeding after malnutrition
Rapid cell uptake/proliferation	Hungry bone syndrome (post-parathyroidectomy), acute leukaemia
Renal losses	
Drugs	Diuretics including acetazolamide and metolazone Tenofovir Imatinib Glucocorticoid/mineralocorticoid therapy
Acute volume expansion	
Hyperparathyroidism—primary and secondary	
Renal transplantation	
Fanconi syndrome	
Primary renal phosphate wasting	
	X-linked hypophosphataemic rickets Autosomal-dominant hypophosphataemic rickets Tumour-induced osteomalacia
Decreased intestinal absorption	
Poor phosphate diet and/or malabsorption	
Phosphate binding antacids	
Steatorrhoea or chronic diarrhoea	
Vitamin D deficiency or resistance	
Renal replacement therapy	

in a similar change within the cell. Elevated pH stimulates glycolysis leading to hypophosphataemia. Respiratory alkalosis may be the precipitating factor in the hypophosphataemia-induced acute rhabdomyolysis that can occur in alcoholic patients; however, the underlying hypophosphataemia may initially be masked by the release of phosphate from injured muscle cells.

Post-parathyroidectomy and sometimes with thyroidectomy, there can be a rapid deposit of calcium and phosphate into the bone, the 'hungry bone syndrome' in those previously osteopenic, which can be symptomatic.

Poor oral intake alone is rarely a sole cause for hypophosphataemia due to the high efficiency of the gut to absorb dietary phosphate and up to 100% renal reabsorption. It can become more of a problem in conditions associated with GI phosphate loss however, such as chronic diarrhoea, vomiting, or the use of aluminium or magnesium containing antacids or other phosphate binding drugs. GI effects are worsened in those with concomitant vitamin D deficiency.

Renal loss of phosphate has a number of causes, most commonly due to the use of diuretic therapy (Table 1). Acute volume expansion can also cause phosphate to decrease due to diminished proximal sodium reabsorption on which phosphate transport closely depends.

Renal replacement therapy is a common cause of hypophosphataemia in the critically ill patient due to loss with effluent waste. Replacement in this situation is important to prevent physiological consequences of hypophosphataemia due to rapid changes in serum concentrations.

Hyperphosphataemia

Hyperphosphataemia can also be attributed to four different mechanisms:

- (i) acute phosphate load,
- (ii) cellular shift,

- (iii) decreased renal clearance,
- (iv) pseudohyperphosphataemia.

Acute phosphate load can be divided into exogenous and endogenous. Exogenous load is uncommon, but has been seen in patients using phosphate-containing laxatives,⁹ which can lead to acute phosphate nephropathy, and those taking high-dose fosphenytoin for the treatment of seizures. These are usually in association with volume contraction (diarrhoea), renal impairment, or both.

Endogenous load is seen more frequently, in tumour lysis syndrome and rhabdomyolysis. Tumour lysis syndrome is commonly caused by chemotherapeutic agents in patients with large tumour burden and rapid cell turnover, such as non-Hodgkins or Burkitt's lymphoma, but can also occur spontaneously in the course of these disease processes. Cell turnover releases potassium, phosphate, purines, and proteins, the latter two of which can be converted to uric acid and urea, respectively, and cause hyperuricaemia. The need for urgent renal replacement therapy may be required as the kidney is overwhelmed with cell components. In rhabdomyolysis, the severity of hyperphosphataemia and hypocalcaemia may be increased if haem pigment-induced acute kidney injury ensues.¹⁰

Acute cellular shifts of phosphate are far less common but can be seen in diabetic ketoacidosis, with severe hyperglycaemia alone, and in lactic acidosis. All types of metabolic acidosis reduce the glycolysis rate and therefore the phosphate taken up into cells. Lactic acidosis is associated with cell death and subsequent release of intracellular phosphate. Consequently, hypophosphataemia can then be seen when these conditions are treated.

Patients with acute or chronic kidney disease develop hyperphosphataemia primarily due to a decrease in glomerular filtration rate. To some extent, this can initially be maintained by suppression of the sodium-phosphate co-transporters in the luminal membrane of the proximal tubules, but below filtration rates of 20–25 ml min⁻¹, phosphate reabsorption is thought to be maximally suppressed, and inevitably leads to an increase

Table 2 Causes of hyperphosphataemia

Acute phosphate load	Tumour lysis syndrome Rhabdomyolysis Exogenous phosphate, for example, sodium phosphate laxative, fosphenytoin
Cellular shift	Metabolic acidosis
Decreased renal clearance	Acute or chronic kidney disease Increased tubular reabsorption • Hypoparathyroidism or pseudohypoparathyroidism • Bisphosphonates • Vitamin D toxicity • Acromegaly • Familial tumoural calcinosis
Pseudohyperphosphataemia	Endogenous • Hyperglobulinaemia • Hyperlipidaemia • Haemolysis • Hyperbilirubinaemia Exogenous • Amphotericin B • Heparin • Tissue plasminogen activator

in plasma levels due to ongoing absorption via the gut. Dysfunctional kidneys are unable to efficiently form 1,25-dihydroxycholecalciferol, leading to a secondary hyperparathyroidism. Additionally, hyperphosphataemia can independently contribute to cardiac causes of death through increased myocardial and vascular calcification, and microcirculatory complications¹¹ in patients with chronic renal failure.

Other causes of decreased renal clearance of phosphate secondary to increased proximal tubular reabsorption can be seen in Table 2.

A pseudohyperphosphataemia can occur due to interference with laboratory analysis in conditions such as hyperglobulinaemia, hyperlipidaemia, hyperbilirubinaemia, and haemolysis. Some drugs can also cause this falsely raised laboratory result, such as amphotericin B and heparin. Values for phosphate should be determined using alternative techniques in these cases.

Consequences of disordered phosphate

As previously discussed, the causes of hypophosphataemia in the critically ill are multifactorial. A combination of sepsis, trauma (in particular, burns and head trauma), acid-base disorders, glucose/insulin therapy, catecholamines, and diuretic use mean that patients in critical care are at much higher risk of hypophosphataemia with higher associated mortality. It is unclear however whether hypophosphataemia contributes directly to this mortality increase, or is a marker of illness severity (Table 3).⁷

Symptomatic hypophosphataemia usually occurs when the phosphate level is lower than 0.32 mmol litre⁻¹.⁸

Symptoms can often be explained due to complications of impaired metabolism—in particular, muscle dysfunction, presenting with acute respiratory failure, failure to wean from ventilation, decreased myocardial contractility with increased inotropic requirement, or with skeletal muscle weakness and rhabdomyolysis. Rhabdomyolysis is more common in those with pre-existing myopathy, e.g. chronic alcoholism, where subsequent hypophosphataemia may precipitate rhabdomyolysis.

Table 3 Adverse clinical effects of severe hypophosphataemia

Respiratory	Acute respiratory failure Impaired diaphragmatic contractility Failure to wean from mechanical ventilation
Cardiovascular	Decreased myocardial contractility, decreased stroke volume Increased inotropic requirement Arrhythmias
Metabolic	Insulin resistance Depletion of 2,3 DPG—oxygen dissociation curve shifts to left
Neurological	Delirium Seizures Coma
Gastrointestinal	Dysphagia Ileus
Haematological	Haemolysis Leucocyte dysfunction—impaired phagocytosis and granulocyte chemotaxis
Musculoskeletal	Weakness Myalgia

Another major cause of symptomatic hypophosphataemia is depletion of 2,3 diphosphoglycerate.⁸ This causes a shift of the oxygen dissociation curve to the left, affecting oxygen delivery to tissues, and in those with chronic lung disease, this effect may be even more marked. Cardiac arrhythmias, both supraventricular and ventricular in origin, can occur alongside this.

Haematological effects of hypophosphataemia seen in the critically ill are those of haemolysis and leucocyte dysfunction—impaired phagocytosis and granulocyte chemotaxis. Dysfunction in leucocytes explains the higher incidence of Gram-negative sepsis in hypophosphataemic patients.⁸

Insulin resistance and ileus are common features seen in the critically ill and postoperative patient group, and can be caused by or contributed to by hypophosphataemia. Altered mental status, delirium, seizures, and coma, have most often been described in the course of refeeding. Hypophosphataemia can also lead to both peripheral and central neuropathies.⁸

Hypocalcaemia and tetany may occur with rapid increases in plasma phosphate due to deposition of calcium into soft tissues. Severe hyperphosphataemia with symptomatic hypocalcaemia can be life threatening, not least because of the negative inotropic effects on the myocardium. Therefore, haemodialysis is often indicated in these patients, particularly in those with pre-existing impaired renal function.

Treatment

Hypophosphataemia does not always necessitate replacement therapy,⁸ as this depends on the body's overall phosphate status. Degrees of severity of hypophosphataemia may lead to either enteral or parenteral replacement.

A serum phosphate level below 0.64 mmol litre⁻¹ (2 mg dl⁻¹) in asymptomatic patients warrants enteral replacement, in patients who are reliably absorbing feed and have adequate vitamin D stores. Enteral phosphate replacement is given in the form of Phosphate Sandoz[®] effervescent tablets. Each tablet contains

PO_4^{3-} 16.1 mmol, Na^+ 20.4 mmol, and K^+ 3.1 mmol. The usual adult dose is up to 6 tablets daily (dissolved in water) in divided doses, to produce a solution that can be given safely via feeding tubes. Tablets should not be taken with aluminium, calcium, or magnesium salts as these will bind phosphate and reduce absorption.

Parenteral phosphate replacement is indicated if the patient has severe hypophosphataemia (<0.32 mmol litre $^{-1}$) or is symptomatic. It may also be considered for patients unlikely to absorb oral agents. A commonly used treatment is the Phosphate Polyfusor[®], a solution containing 50 mmol PO_4^{3-} , 9.5 mmol K^+ , and 81 mmol Na^+ in 500 ml, given over 24 h via a central venous catheter. This preparation should be infused alone, via a dedicated port of a central line, and if given peripherally should have a dedicated cannula. Peripherally, the ideal is to reduce the rate of infusion due to risk of pain and phlebitis at the injection site, but with close monitoring could be given at the same rate as the central dose.

Caution should be taken in those with renal impairment, as in this particular group, the risk of iatrogenic hyperphosphataemia is significant. Phosphate replacement may exacerbate hypocalcaemia and can cause metastatic soft tissue calcification. At least, daily monitoring is necessary for those having treatment to reduce the risk of hyperphosphataemia. Calcium should be corrected before administration of phosphate replacement.

Phosphate Sandoz[®] and Phosphate Polyfusor[®] contain a relatively high dose of sodium which may be unsuitable for some patients requiring phosphate replacement.

Another common replacement regimen includes that of i.v. potassium phosphates. Products can be a combination of monobasic potassium phosphate and dibasic potassium phosphate. They must be diluted before use in either 0.9% sodium chloride or 5% glucose to a minimum volume of 100 ml, and given at a rate of no greater than 20 mmol of phosphate per hour preferably via a central line. This avoids administrations of high-sodium content fluid, and in patients requiring potassium replacement and phosphate, can be very useful. Dose should be titrated against plasma phosphate and potassium levels regularly to avoid hyperphosphataemia and hyperkalaemia.

Alternatively, potassium acid phosphate (potassium dihydrogen phosphate) with a neat concentration of 1 mmol ml $^{-1}$ each of potassium and phosphate can be used. Other alternatives such as Glycophos[®] (20 mmol phosphate, 40 mmol sodium in 20 ml solution) or Addiphos[®] (40 mmol phosphate, 30 mmol potassium, and 30 mmol sodium in 20 ml solution) can be added to i.v. fluids including TPN.

Hyperphosphataemia should be treated by correction of the underlying cause. In the case of rapid cell turnover or rhabdomyolysis, renal replacement therapy may be indicated and should be instituted promptly.

Summary

Phosphate disturbances in critically ill patients are relatively common, often multifactorial, and can occasionally have catastrophic consequences if not monitored and treated appropriately. Transient changes may be left without intervention due to rapid movement between intracellular and extracellular spaces if the patient remains asymptomatic. Correction of phosphate

disturbances should be done carefully with close monitoring, regular review, and a thorough knowledge of the pharmacology and physiology and an understanding of the potential pitfalls of standard laboratory monitoring.

Declaration of interest

None declared.

MCQs

The associated MCQs (to support CME/CPD activity) can be accessed at <https://access.oxfordjournals.org> by subscribers to BJA Education.

References

1. Shaikh A, Berndt T, Kumar R. Regulation of phosphate homeostasis by the phosphatonins and other novel mediators. *Paediatr Nephrol* 2008; **23**: 1203–10
2. Fleet JC, Peacock M. Physiology of vitamin D, calcium, and phosphate absorption. In: Morris HA, Anderson PH, Nordin BEC, eds. *The Physiological Basis of Metabolic Bone Disease*. CRC Press, 2014; 13–35
3. Schiavi SC, Kumar R. The phosphatonin pathway: new insights in phosphate homeostasis. *Kidney Int* 2004; **65**: 1–14
4. Rose BD, Post TW. Hormonal regulation of calcium and phosphate balance. Available from http://www.uptodate.com/contents/regulation-of-calcium-and-phosphate-balance?source=search_result&search=chapter+6f+hormonal+regulation+of+calcium+and+phosphate+balance&selectedTitle=1-150 (accessed 26 May 2016)
5. Yu ASL, Stubbs JR. Causes of hypophosphataemia, and evaluation and treatment of hypophosphataemia. Available from http://www.uptodate.com/contents/causes-of-hypophosphatemia?source=search_result&search=causes+of+hypophosphatemia&selectedTitle=1-150 (accessed 26 May 2016)
6. Suzuki S, Egi M, Schneider AG, Bellomo R, Hart G, Hegarty C. Hypophosphatemia in critically ill patients. *J Crit Care* 2013; **28**: 536.e9–19
7. Geerse DA, Bindels AJ, Kuiper MA, Roos AN, Spronk PE, Schultz MJ. Treatment of hypophosphataemia in the intensive care unit: a review. *Crit Care* 2010; **14**: R147
8. Gaasbeek A, Meinders AE. Hypophosphatemia: an update on its etiology and treatment. *Am J Med* 2005; **118**: 1094–101
9. Tan HL, Liew QY, Loo S, Hawkins R. Severe hyperphosphataemia and associated electrolyte and metabolic derangement following the administration of sodium phosphate for bowel preparation. *Anaesthesia* 2002; **57**: 478–83
10. Stubbs JR, Yu ASL. Overview of the causes and treatment of hyperphosphataemia. Available from http://www.uptodate.com/contents/overview-of-the-causes-and-treatment-of-hyperphosphatemia?source=search_result&search=overview+of+the+causes+and+treatment+of+hyperphosphatemia&selectedTitle=1-150 (accessed 4 October 2016)
11. Albaaj F, Hutchinson AJ. Hyperphosphataemia in renal failure: causes, consequences and current management. *Drugs* 2003; **63**: 577–96